Hematologists are frequently consulted for management recommendations for patients receiving long-term oral antithrombotic therapy who require temporary interruption of anticoagulation prior to surgery or an invasive procedure. It is currently estimated that approximately 250,000 patients in North America will require interruption of oral anticoagulant therapy each year 1 . The management of these patients, however, is problematic. On the one hand, disruption of oral anticoagulant therapy will expose the patient to an increased risk for thromboembolism, but the degree of risk is clearly variable among such patients. On the other hand, there is an increased risk for hemorrhagic complications if anticoagulant therapy is continued, which is affected by the type of surgery or invasive procedure that the patient will undergo. In addition, maintaining full anticoagulant therapy in the perioperative setting has the potential to inadvertently lead to an increased risk for thromboembolism in those patients who sustain a hemorrhagic event and subsequently have their anticoagulant therapy held or even reversed. For the individual patient, therefore, these issues must be considered prior to formulating management recommendations.
Although this clinical situation is not uncommon, there is relatively limited evidence available to guide therapeutic recommendations. In addition, we are entering a rapidly changing landscape, with two novel oral anticoagulants recently approved for use in patients with atrial fibrillation, and several other agents currently either under review or being studied (Table 1) . These agents introduce new issues and concerns with perioperative management, and will be discussed below. In addition, there is an expanding array of antiplatelet agents in use, which also need to be considered in the perioperative period (Table 2) . This article will focus on the pre-operative assessment of patients on these various antithrombotic therapies and discuss management strategies for this frequently encountered clinical situation.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Surgical procedures differ in their risk for bleeding, although there are limited data identifying the relative risk for bleeding associated with different procedures 1 . Procedures involving highly vascular organs, such as the liver, kidney, and spleen, have a higher risk for bleeding even in the absence of perioperative antithrombotic drug administration. Other procedures associated with an increased risk for bleeding include urologic surgery, bowel resection, and colonic polyp resection, especially for large, sessile polyps, and major surgery associated with extensive tissue injury (for example, cancer surgery, joint arthroplasty). Certain procedures, such as implantation of a pacemaker or cardioverter/defibrillator, or intracranial or spinal surgery, may not intrinsically exhibit an increased risk of hemorrhage, but even a small amount of excess bleeding in these confined locations can be associated with an adverse outcome 11 .
Perioperative Management of Patients on Chronic Vitamin K-Antagonist Therapy
Procedures Associated with a Low Bleeding Risk. Interruption of oral anticoagulant therapy may not be necessary in patients undergoing certain procedures with a low bleeding risk. In general, interruption of warfarin is not required for minor dental procedures, including tooth extractions and endodontal procedures 11 . Continuing warfarin with concomitant administration of a prohemostatic agent (e.g., an antifibrinolytic agent, such as tranexamic acid or aminocaproic acid used as a mouthwash prior to and following the dental work), or interrupting warfarin for only 2 to 3 days, resulting in an INR that is slightly subtherapeutic at the time of the procedure, are reasonable management strategies 1 . Similarly, interruption of warfarin therapy is generally not necessary for patients undergoing minor skin excisions, such as treatment of basal and squamous cell skin cancers and actinic keratosis. Although a higher incidence of minor skin bleeding was reported in patients who continued warfarin compared to those who interrupted warfarin therapy, most bleeds were self-limited 1, 12 . In contrast to most dental and dermatologic procedures, cataract removal is generally an avascular procedure. In a recent systematic review and meta-analysis, patients who underwent cataract surgery while on vitamin will need to be interrupted in order to safely conduct the surgery or invasive procedure. For patients assessed as having a low risk for thromboembolic complications (Table 3) , warfarin can simply be stopped prior to the procedure, typically beginning five days before, and then resumed once the procedure has been completed. The overall time that the patient will be subtherapeutic on warfarin may range from several days to a week or more, but if the risk for thromboembolism is considered low enough during this relatively brief period of time, then this approach represents the safest strategy.
Patients assessed as having a moderate to high risk for thromboembolic complications raise greater concern for the possibility of a thromboembolic event during the period of time when the INR is subtherapeutic. For these patients, a short-acting agent such as unfractionated heparin or LMWH may be used as a "bridge" during the time when the INR is subtherapeutic, to decrease the period of time when the patient is at risk for thromboembolism. The risk with this approach, however, is the potential for hemorrhage when anticoagulants are employed too near the time of the surgery or procedure, and care must be taken with the planned timing of stopping and re-starting the short-acting agent. Although conceptually this process may sound relatively simple, the devil lies in the details given the various combinations of when to stop and when to restart each agent, as well as the doses employed, and the potential for adverse outcomes that may occur with each of these strategies. (e.g., neurosurgery, cardiovascular surgery), or with spinal anesthesia, consideration should be given to stopping the drug 2 to 4 days prior to the procedure. As renal function declines, the half-life of the drug prolongs, and it will need to be held for at least 2 days (with a creatinine clearance between 30 and 50 mL/min) or longer (if creatinine clearance is ≤ 30 mL/min), even for low risk procedures. Rivaroxaban is cleared to a lesser extent by the kidney (66%) 22 and in most patients can be safely stopped within 1 to 2 days prior to the procedure 24 . As with dabigatran, however, a more conservative approach would be to consider withholding the drug for a longer period of time in patients with significant renal impairment.
Interruption of the vitamin

Resumption of the new oral anticoagulants after surgery. For patients undergoing major
abdominal procedures or urologic surgery, the new oral anticoagulants should not be restarted until after all postoperative bleeding has stopped, given their rapid onset of action (Table 1) .
One strategy that has been suggested is to use a lower dose of dabigatran (e.g., 75 mg) or rivaroxaban (e.g., 10 mg) for the initial dose after surgery, followed by resumption of the usual maintenance dose if no bleeding is encountered 24 .
Laboratory testing in the perioperative setting. Although routine laboratory monitoring is not necessary for dabigatran and rivaroxaban, some individuals may wish to use laboratory testing to confirm the lack of any residual anticoagulant effect prior to surgery. For patients taking dabigatran, a thrombin time prior to surgery can be helpful, since this test is particularly sensitive to the presence of dabigatran 23 . The thrombin time is extremely sensitive to dabigatran, and in some patients a dilute thrombin time that has been calibrated to clinically relevant concentrations of dabigatran may be preferable, if available 23 . For patients taking rivaroxaban, the sensitivities of various PT and aPTT reagents vary in their ability to detect low levels of circulating drug 25 . Anti-factor Xa chromogenic assays, similar to those used to measure heparin levels, are being evaluated and may prove useful for patients taking rivaroxaban 26 .
Use of bridging anticoagulation. Bridging therapy with a LMWH or unfractionated heparin is not necessary with the new oral anticoagulants, given the relatively rapid clearance of the drug from the circulation, and the rapid onset of action when re-introduced (Table 1) .
Perioperative Management of Patients on Chronic Antiplatelet Therapy.
Antiplatelet drugs that irreversibly inhibit platelet function include aspirin and the thienopyridines clopidogrel, ticlopidine, and prasugrel (Table 2) . Ticagrelor is a direct-acting, reversibly-binding, oral P2Y 12 receptor antagonist that exhibits a rapid onset and offset of antiplatelet effect 27 .
Other reversible antiplatelet drugs include dipyridamole and cilostazol, and the non-steroidal anti-inflammatory agents also have a transient antiplatelet effect. Newer antiplatelet agents that are currently being studied in clinical trials include cangrelor and elinogrel. Cangrelor is an intravenous agent that has an excellent acute profile, with a rapid onset of action, a rapid offset, and a half-life of just a few minutes (Table 2) 28 . Perioperative management of these agents presents some additional challenges not encountered with the anticoagulant therapies.
Assessment of thromboembolic risk. Antiplatelet medications are used for the primary and secondary management of atherosclerotic thrombotic disease, particularly in the management of patients with stroke, acute myocardial infarction or acute coronary syndromes, or peripheral vascular disease, as well as patients undergoing percutaneous coronary intervention or cardiac surgery 29 . Dual antiplatelet therapy with a thienopyridine in combination with aspirin has been shown to dramatically reduce the incidence of adverse events in patients receiving coronary artery stents, and premature discontinuation of antiplatelet therapy is associated with an increased risk of stent thrombosis, myocardial infarction, and death. Consequently, a recent science advisory from the American Heart Association, the American College of Cardiology, and other organizations stressed the importance of twelve months of dual antiplatelet therapy after Although these therapeutic agents have relatively short half-lives, the most frequently used agents (aspirin, clopidogrel) irreversibly inhibit platelet function, necessitating withholding their administration for 7 to 10 days prior to surgery or an invasive procedure that requires complete elimination of the antiplatelet effect (Table 2) . No randomized trials have assessed whether withholding antiplatelet therapy for a shorter period of time would provide a safer approach.
Resumption of antiplatelet therapy after surgery. The maximal antiplatelet effect occurs within minutes after resumption of aspirin (Table 2 ). In contrast, the maximal antiplatelet effect of clopidogrel may not be reached until after seven days of daily administration of a standard dose (75 mg/day), but this can be shortened by administering an initial loading dose 29 . 
Future directions.
Several clinical trials are currently open and enrolling patients into studies designed to address some of the deficiencies noted above. For example, although bridging anticoagulation with a low-molecular weight heparin is frequently used in patients on chronic warfarin therapy who need their anticoagulation held for a procedure, there is no firm evidence that this approach actually prevents perioperative thromboembolic events. BRIDGE is a prospective randomized trial supported by the National Heart, Lung, & Blood Institute that is enrolling patients with atrial fibrillation or flutter who require temporary interruption of warfarin for a surgery or procedure.
The study compares bridging with therapeutic-dose low-molecular weight heparin to placebo (clinicaltrials.gov #NCT00786474). PERI-OP2 is a second trial that is also designed to study the safety and efficacy of low-molecular weight heparin as a bridge for patients with atrial fibrillation or prosthetic aortic valves who need anticoagulation withheld for a procedure (clinicaltrials.gov #NCT00432796). These two studies will address the issue of efficacy and safety of bridging therapy in patients on chronic warfarin anticoagulant therapy. 
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